This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saiman, L Articles by Prince, A Search for Related Content PubMed PubMed Citation Articles by Saiman, L Articles by Prince, A

 Previous Article  |  Next Article 

Infect Immun. 1989 September; 57(9): 2764-2770

Cross-reactivity of Pseudomonas aeruginosa antipilin monoclonal antibodies with heterogeneous strains of P. aeruginosa and Pseudomonas cepacia.

Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York 10032.

ABSTRACT

Much of the morbidity and mortality in patients with cystic fibrosis (CF) is secondary to pulmonary infections with Pseudomonas aeruginosa and, more recently, with Pseudomonas cepacia. Prevention of colonization and subsequent infection would be a useful therapeutic strategy. The pili (fimbriae) of P. aeruginosa are a potential vaccine antigen, as they have been implicated in binding to respiratory epithelium and appear to have limited antigenic diversity. Monoclonal antibodies (MAbs) raised to P. aeruginosa pilin demonstrated significant cross-reactivity, as four of five P. aeruginosa strains with known pilin sequences and 10 of 15 P. aeruginosa clinical isolates hybridized by immunoblot with at least one of the three MAbs tested. The P. cepacia strains demonstrated minimal cross-reactivity with these MAbs, as only 2 of 16 strains hybridized immunologically. The three MAbs decreased the adherence of 35S-labeled P. aeruginosa PA1244 to bovine tracheal cells by 56, 45, and 31%. One of these MAbs decreased the adherence of strains P. aeruginosa PAO1 and P. cepacia 249 to CF epithelial cells by 46 and 25%, respectively. While antibodies to Pseudomonas pili must be shown to be protective in patients with CF, these studies give support for a multivalent vaccine strategy using P. aeruginosa pilin as the immunogen.

This article has been cited by other articles:

• Horzempa, J., Comer, J. E., Davis, S. A., Castric, P. (2006). Glycosylation Substrate Specificity of Pseudomonas aeruginosa 1244 Pilin. J. Biol. Chem. 281: 1128-1136 [Abstract] [Full Text]  
• Smedley, J. G. III, Jewell, E., Roguskie, J., Horzempa, J., Syboldt, A., Stolz, D. B., Castric, P. (2005). Influence of Pilin Glycosylation on Pseudomonas aeruginosa 1244 Pilus Function. Infect. Immun. 73: 7922-7931 [Abstract] [Full Text]  
• Kus, J. V., Tullis, E., Cvitkovitch, D. G., Burrows, L. L. (2004). Significant differences in type IV pilin allele distribution among Pseudomonas aeruginosa isolates from cystic fibrosis (CF) versus non-CF patients. Microbiology 150: 1315-1326 [Abstract] [Full Text]  
• PLOTKOWSKI, M. C., COSTA, A. O., MORANDI, V., BARBOSA, H. S., NADER, H. B., BENTZMANN, S. D., PUCHELLE, E. (2001). Role of heparan sulphate proteoglycans as potential receptors for non-piliated Pseudomonas aeruginosa adherence to non-polarised airway epithelial cells. J Med Microbiol 50: 183-190 [Abstract] [Full Text]